Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
-
Adult
-
Aged
-
Aged, 80 and over
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antigens, CD
-
Antigens, Differentiation, Myelomonocytic
-
Clinical Trials, Phase II as Topic
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Evaluation Studies as Topic
-
Female
-
Follow-Up Studies
-
Humans
-
Leukemia, Myeloid, Acute
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Recurrence
-
Risk Assessment
-
Severity of Illness Index
-
Sialic Acid Binding Ig-like Lectin 3
-
Single-Blind Method
-
Survival Rate
-
Treatment Outcome